

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10560317	
	Filing Date		2006-07-13	
	First Named Inventor	Frank LEENDERS		
	Art Unit	1651		
	Examiner Name	Thane E. UNDERDAHL		
	Attorney Docket Number	14836-53313		

U.S. PATENTS						
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	6271381	B1	2001-08-07	YUGAWA et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S. PATENT APPLICATION PUBLICATIONS						
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS								
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10560317
Filing Date		2006-07-13
First Named Inventor	Frank LEENDERS	
Art Unit	1651	
Examiner Name	Thane E. UNDERDAHL	
Attorney Docket Number	14836-53313	

1	HOLCENBERG, J.S., et al., "Enhanced effect of an L-glutamine antagonist, L-(alphaS,5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid, by Acinetobacter L-glutaminase-L-asparaginase", Cancer Treat Rep, Vol.63, pp.1109-1114 (1979). (Abstract only)	<input type="checkbox"/>
2	JARACZ, S., et al., "Recent advances in tumor-targeting anticancer drug conjugates", Bioorganic & Medicinal Chemistry, Vol.13, pp.5043-5054 (2005).	<input type="checkbox"/>
3	BARABAS, K., et al., "Transferrin conjugates of adriamycin are cytotoxic without intercalating nuclear DNA", J Biol Chem., Vol.267, pp.9437-9442 (1992).	<input type="checkbox"/>
4	BURTIS, C., et al., "Glossary of bioanalytical nomenclature - Part 1: General terminology, body fluids, enzymology, immunology", Pure and Applied Chemistry, Vol.66, pp.2587 - 2604 (1994).	<input type="checkbox"/>
5	UMEZAWA, K., et al., "Mutagenicity of Aclacinomycin A and Daunomycin Derivatives", CANCER RESEARCH, Vol.38, pp.1782-1784 (1978).	<input type="checkbox"/>
6	GRIFFITHS, G., et al., "Cure of SCID mice bearing human B-lymphoma xenografts by an anti-CD74 antibody-anthracycline drug conjugate", Clin Cancer Res., Vol.9, pp.6567-6571 (2003).	<input type="checkbox"/>
7	GRUBER, B.M., et al., "The effect of new anthracycline derivatives on the induction of apoptotic processes in human neoplastic cells", FOLIA HISTOCHEMICA, Vol.42, pp.127-130 (2004).	<input type="checkbox"/>
8	SHIH, L.B., "Anthracycline immunoconjugates prepared by a site-specific linkage via an amino-dextran intermediate carrier", Cancer Res., Vol.51, pp.4192-8 (1991).	<input type="checkbox"/>
9	YOON, E.J., "Pharmacokinetics of DA-125, a new anthracycline, after intravenous administration to uranyl nitrate-induced acute renal failure rats or protein-calorie malnutrition rats", Biopharm Drug Dispos., Vol.17, pp.183-95 (1996).	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT****(Not for submission under 37 CFR 1.99)**

Application Number	10560317
Filing Date	2006-07-13
First Named Inventor	Frank LEENDERS
Art Unit	1651
Examiner Name	Thane E. UNDERDAHL
Attorney Docket Number	14836-53313

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.